Second-generation CAR-T incorporating the B10 binder (B10-CAR), designed to target an HLA-A*24:02/DNAJB8-derived peptide complex on RCC cells [103], shows antigen and HLA-dependent activation and IFNγ production with human RCC cell lines in vitro and a significant reduction in tumour burden in vivo (p < 0.01). Here, HLA-A is linked to renal cell carcinoma.